References
- Genazzani A R, Schneider H PG, Panay N, Nijland E A. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006; 22: 369–375
- Pickar J H, Yeh I T, Wheeler J E, Cunnane M F, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003; 80: 1234–1240
- Notelovitz M, Lenihan J P, McDermott M, Kerber I J, Nanavati N, Arce J-C. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95: 726–731
- Panay N, Ylikorkala O, Archer D F, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopause symptom relief. Climacteric 2007; 10: 120–131
- Lundström E, Bygdeson M, Svane G, Azavedo E, von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007; 10, 249–56
- Sturdee D W, MacLennan A H. Reducing the problems of the progestogen. Climacteric 2006; 9: 241–243
- Panay N, Studd J WW. Progestogen intolerance and compliance with hormone replacement therapy. Hum Reprod Update 1997; 3: 159–171
- Greenwald M W, Gluck O S, Lang E, Rakov V. Oral hormone therapy with 17 beta-estradiol and 17 beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005; 12: 741–748
- Ettinger B, Kristine E, Ensrud E, et al. Effects of ultra low-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104: 443–451
- Manson J E, Bassuk S S, Harman S M, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006; 13: 139–147
- Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448–454
- White W B, Hanes V, Chauhan V, Pitt B. Effects of a new HT, drospirenone and 17β-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48: 246–253
- Sturdee D W, Rantala M L, Colau J C, Zahradnik H-P, Riphagen F E, for the multicenter MLS Investigators. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric 2004; 7: 404–411
- Buster J, Kingsberg S A, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105: 944–952
- Shifren J, Davis S R, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopause women: results from the INTIMATE NM1 Study. Menopause 2006; 13: 1–10
- Deecher D C, Alfinito P, Leventhal L, et al. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007; 148: 1376–1383
- Pickar J. Phase II trial of a TSEC (tissue selective estrogen complex) bazedoxifene/CEE in postmenopausal women. Presented at the 6th International Menopause Society Workshop, Pisa, December, 2006